Fulcrum Therapeutics, Inc. (FULC) saw its stock plummet by over 60% after its phase III REACH study for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD) failed to meet its primary endpoint. While this news is a setback for the company, Fulcrum remains focused on its other pipeline candidate, pociredir, for sickle cell disease, which has garnered significant attention and potential.
Fulcrum Therapeutics’ stock plunged after the Phase 3 REACH trial evaluating losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The study’s results contradict the positive findings observed in the Phase 2 trial, leading Fulcrum to suspend the losmapimod program for FSHD.
BofA Securities has upgraded Fulcrum Therapeutics (FULC) ahead of the company’s Phase 3 readout for losmapimod, a potential treatment for Facioscapulohumeral muscular dystrophy (FSHD). The analyst cites optimism from key opinion leaders about the upcoming results, based on the functional benefits seen in Phase 2 using the ‘reachable workspace’ (RWS) endpoint. While the analyst acknowledges uncertainties about the study’s success, they have increased the likelihood of success from 35% to 50%.
